Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

19991,007 citationsJournal Articlebronze Open Access

Authors

Schlomo Staszewski · Goethe University Frankfurt

Javier O Morales-Ramirez · Clinical Research Puerto Rico

Karen T. Tashima

Anita Rachlis · University of Toronto

Daniel J. Skiest · The University of Texas Southwestern Medical Center

James Stanford · University of Missouri–Kansas City

Richard Stryker

Philip C. Johnson

Abstract

As antiretroviral therapy in HIV-1-infected adults, the combination of efavirenz, zidovudine, and lamivudine has greater antiviral activity and is better tolerated than the combination of indinavir, zidovudine, and lamivudine.

Topics & Keywords

HIV/AIDS drug development and treatment HIV Research and Treatment HIV/AIDS Research and Interventions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 341, Issue 25, pp. 1865-1873

DOI: 10.1056/nejm199912163412501

Field-Weighted Citation Impact: 45.60